Hypophosphatasia Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Hypophosphatasia remains an active clinical development field. One-time and precision therapies are raising the efficacy ceiling, but durability, manufacturing, small-population evidence and long-term safety remain decisive constraints. The PatSnap evidence set used here contains 20 matched trial records and 19 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07390240 | Intervention not normalized | Not Applicable; Recruiting | AstraZeneca PLC | Russia | (1) Mean age (in full years) at the HPP diagnosis; (Day 0 (Visit 1)); (2) Mean age at the onset of initial HPP symptoms (including separately any, skeletal, and non-skeletal symptoms); (Day 0 (Visit 1)) | 2027-06-30 |
| JPRN-jRCT2053250167 | REC-01(PuREC) | Phase 1/2; 募集前 | PuREC KK | Japan | Safety: Adverse events, malfunctions; 安全性：有害事象、不具合 | 2028-03-31 |
| NCT07179640 | OC-1(1cBio) | Phase 1/2; Recruiting | Alesta Therapeutics | New Zealand, United Kingdom | Evaluate the safety of ALE1 by assessing the number of treatment emergent adverse events (TEAEs) (From baseline up to day 16); Evaluate safety of ALE1 by assessing the presence of clinically significant changes in participants haematology parameters post-dose (From baseline up to day 16) | 2027-01-01 |
| ChiCTR2500099011 | Teriparatide(Eli Lilly) | Not Applicable; Recruiting | Shanghai Sixth People's Hospital | China | bone mineral density; alkaline phosphatase | 2030-08-31 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Alesta to Highlight ALE1 Clinical Progress at 44th Annual JP Morgan Healthcare Conference (Phase 1/2): the indexed record reports Safety = favorable and supportive of continued development.
- Open-Label Pilot Trial to Evaluate the Effects of Ilofotase Alfa on Biomarkers in Adult Patients With Hypophosphatasia (Phase 1/2): the indexed record reports Maximum Percent Change From Baseline in Extracellular Inorganic Pyrophosphate (PPi)(Mean) = -77.31 percent change (Standard Deviation, 16.113); Maximum Percent Change From Baseline in Extracellular Inorganic Pyrophosphate (PPi)(Mean): Mean Difference (Final Values) = 40.85(95% CI, 22.842 - 58.858), P-Value = 0.0005; Difference in LS Means = -11.17(95% CI, -16.52 to -5.82), P-Value = <0.0001; Maximum Percent Change From Baseline in Extracellular Inorganic Pyrophosphate (PPi)(Mean) = -36.46 percent change (Standard Deviation, 11.502).
- Safety, Pharmacokinetics, and Pharmacodynamics of Efzimfotase Alfa, a Second-generation Enzyme Replacement Therapy: Phase 1, Dose-escalation Study in Adults with Hypophosphatasia. (Phase 1): the indexed record reports ADA = 27 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including REC-01(PuREC) (Preclinical), OC-1(1cBio) (Phase 1/2; ENPP1), Teriparatide(Eli Lilly) (Approved; PTH1R). Company & Deal Intelligence records identify sponsor context for AstraZeneca PLC (AZN), PuREC KK, Alesta Therapeutics, Shanghai Sixth People's Hospital. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Natural-history-aligned endpoints that remain interpretable in small heterogeneous cohorts.
- Long-term registries for durability, immunogenicity and delayed safety signals.
- Redosing, rescue and treatment-sequencing strategies after incomplete response.
- Access models that address diagnosis, manufacturing and global delivery.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Hypophosphatasia has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
